Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessMorgan Stanley Upgrades Sarepta Therapeutics, Inc. to Overweight

Morgan Stanley Upgrades Sarepta Therapeutics, Inc. to Overweight

Add to Favorite
Added to Favorite


Morgan Stanley has upgraded Sarepta Therapeutics to Overweight, signaling confidence in the company’s future following FDA’s expanded approval of Elevidys for Duchenne muscular dystrophy (DMD).
The FDA’s decision for both traditional and accelerated approval of Elevidys highlights its potential to significantly improve the DMD treatment landscape.
The stock’s surge by 5.09% to $123.5 post-announcement reflects investor confidence in Sarepta’s growth trajectory and the market impact of Elevidys.

Morgan Stanley’s upgrade of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to Overweight, as reported by TheFly, comes at a pivotal moment for the company. Sarepta Therapeutics, a leader in genetic medicine for rare diseases, has recently achieved a significant milestone with the FDA’s expanded approval of its gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD). This approval, covering all patients aged four and older with a confirmed mutation in the DMD gene, marks a major advancement in the treatment of this genetic disorder.
The FDA’s decision to grant both traditional and accelerated approval for Elevidys underscores the therapy’s potential to significantly improve the treatment landscape for DMD. Traditional approval for ambulatory patients acknowledges the functional benefits of the treatment, while accelerated approval for non-ambulatory patients indicates a promising path forward, contingent upon further verification of clinical benefits. This broad label approval could potentially enhance Sarepta’s market position and financial outlook, aligning with Morgan Stanley’s optimistic assessment.
The stock’s surge by 5.09% to $123.5 following the announcement, reflects investor confidence in Sarepta’s growth trajectory and the potential market impact of Elevidys. With a market capitalization of approximately $11.67 billion and a trading volume of 1,234,412 shares, SRPT’s performance is closely watched by investors. The stock’s price movement, ranging between $55.25 and $146.68 over the past year, further highlights its volatility and the high stakes involved in the biotech sector.
Sarepta’s commitment to advancing care for DMD patients through precision genetic medicine is evident in this FDA approval. The company’s focus on developing treatments for rare diseases positions it as a key player in the biotech industry, competing with other firms aiming to address unmet medical needs. The FDA’s expanded approval of Elevidys not only represents a significant achievement for Sarepta but also offers hope to patients and families affected by Duchenne muscular dystrophy.

Subscribe to get Latest News Updates

Latest News

You may like more
more